Stoke Therapeutics initiates Phase 3 EMPEROR study of zorevunersen; first US sites in May 2025

Stoke Therapeutics, Inc.

Initiated Phase 3 EMPEROR study of zorevunersen; first U.S. sites activated in May 2025.
Updated corporate presentation posted to website on June 4, 2025, for Jefferies Global Healthcare Conference.
No other material financial or operational updates disclosed beyond the study initiation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.